| |
Jan 17, 2001
Rhone Poulenc: Ace after the takeover
Rhone Poulenc has declared impressive results with a 30.3% growth in net profit on the back of a 18% rise in the sales. The operating margins have increased by 90 basis points in the current quarter vis–a–vis the corresponding quarter of the last year.
Rhone is the second biggest player in the Rs 4.84 bn cough and colds segment after Pfizer. It's product Phensedyl ranks only next to Pfizer's Corex in terms of market share. The product which grew by 21% last year, contributes more than 15% to the company's turnover.
| (Rs m) |
3QFY00 |
3QFY01 |
Change |
| Sales |
517 |
610 |
18.0% |
| Other Income |
21 |
33 |
53.7% |
| Expenditure |
432 |
505 |
16.8% |
| Operating Profit (EBDIT) |
85 |
106 |
24.1% |
| Operating Profit Margin (%) |
16.4% |
17.3% |
|
| Interest |
1 |
1 |
|
| Depreciation |
7 |
7 |
-9.6% |
| Profit before Tax |
98 |
131 |
33.5% |
| Other Adjustments |
|
- |
|
| Tax |
34 |
48 |
39.7% |
| Profit after Tax/(Loss) |
64 |
84 |
30.3% |
| Net profit margin (%) |
12.4% |
13.7% |
|
| Earnings per share* |
56.98 |
74.22 |
|
| *annualised |
|
|
|
A 40% stake in the company was recently acquired by Nicholas Piramal, which has made an open offer for another 20% stake under the SEBI guidelines at a price of Rs 875.
The stock quotes at Rs 760, which implies an earnings multiple of less than 11 times 3QFY01 annualised earnings.
More Views on News
Aug 14, 2017
A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.
Aug 14, 2017
GST impact coupled with price erosion in US leads to lower profits for the quarter.
Aug 8, 2017
Profits plunge due to higher raw material costs.
Jun 23, 2017
Net Profit lower due to exceptional items in the previous year.
May 30, 2017
US markets decline while other geographies grow in the quarter.
More Views on News
Most Popular
Aug 7, 2017
The data tells us quite a different story from the one the government is trying to project.
Aug 10, 2017
Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.
Aug 8, 2017
Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 7, 2017
Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...
More
Copyright © Equitymaster Agora Research Private Limited. All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results. SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407 | |
|
|
Equitymaster requests your view! Post a comment on "Rhone Poulenc: Ace after the takeover". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!